The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

Derek J Erstad; Andrew M Tager; Yujin Hoshida; Bryan C Fuchs

doi:10.1080/23723556.2017.1311827

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

Mol Cell Oncol. 2017 Mar 31;4(3):e1311827. doi: 10.1080/23723556.2017.1311827. eCollection 2017.

Authors

Derek J Erstad¹, Andrew M Tager², Yujin Hoshida³, Bryan C Fuchs¹

Affiliations

¹ Division of Surgical Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
² Center for Immunology and Inflammatory Diseases, Fibrosis Research Center, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
³ Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Abstract

Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.

Keywords: ATX; HCC; LPA; LPAR1; NASH; chemoprevention; cirrhosis; fibrosis; hepatocellular carcinoma; non-alcoholic steatohepatitis.

Abstract

Grants and funding